Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers*
References (36)
- et al.
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Neuropharmacology
(2007) - et al.
Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV
Addict Behav
(1999) - et al.
Effects of gender on relapse prevention in smokers treated with bupropion SR
Am J Prev Med
(2002) - et al.
Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire
Addict Behav
(2007) - et al.
The Tobacco Atlas
(2006) - et al.
Impact of smoking habit on medical care use and its costs: A prospective observation of National Health Insurance beneficiaries in Japan
Int J Epidemiol
(2001)
Nicotine replacement therapy for smoking cessation
Cochrane Database Syst Rev
(2004)
Antidepressants for smoking cessation
Cochrane Database Syst Rev
(2007)
The health consequences of smoking: Nicotine addiction: A report of the Surgeon General
(1988)
Pathophysiology of tobacco dependence
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
Nature
(2005)
Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation
J Med Chem
(2005)
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial [published correction appears in JAMA. 2006;296:1355]
JAMA
(2006)
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial
JAMA
(2006)
Cited by (170)
Comparative efficacy and safety of pharmacological interventions for smoking cessation in healthy adults: A network meta-analysis
2021, Pharmacological ResearchCitation Excerpt :The stepwise process of the study selection has been presented through the PRISMA flow chart (Fig. 1). The vital study characteristics of each included study have been summarized in eTable 1 [26–122]. Risk of bias was assessed by assessing each of the seven domains of risk of bias for individual studies and represented in eTable 2.
Nicotine receptor partial agonists for smoking cessation
2023, Cochrane Database of Systematic ReviewsThe Usefulness of a Smartphone App-Based Smoking Cessation Program for Conventional Cigarette Users, Heated Tobacco Product Users, and Dual Users: Retrospective Study
2023, Journal of Medical Internet Research
- *
The data in this manuscript were presented in part at the 2006 Scientific Sessions of the American Heart Association, November 12–15, 2006, Chicago, Illinois.
Copyright © 2007 Published by Elsevier Inc.